Procalcitonin is Expressed in Osteoblasts and Limits Bone Resorption Through Inhibition of Macrophage Migration During Intermittent PTH Treatment

Overview

Journal Bone Res

Specialties Endocrinology
Orthopedics

Date 2022 Jan 28

PMID 35087025

Authors

Anke Baranowsky

Denise Jahn

Shan Jiang

Timur Yorgan

Peter Ludewig

Jessika Appelt

Kai K Albrecht

Ellen Otto

Paul Knapstein

Antonia Donat

Jack Winneberger

Lana Rosenthal

Paul Kohli

Cordula Erdmann

Melanie Fuchs

Karl-Heinz Frosch

Serafeim Tsitsilonis

Michael Amling

Thorsten Schinke

Johannes Keller

Affiliations

Soon will be listed here.

Abstract

Intermittent injections of parathyroid hormone (iPTH) are applied clinically to stimulate bone formation by osteoblasts, although continuous elevation of parathyroid hormone (PTH) primarily results in increased bone resorption. Here, we identified Calca, encoding the sepsis biomarker procalcitonin (ProCT), as a novel target gene of PTH in murine osteoblasts that inhibits osteoclast formation. During iPTH treatment, mice lacking ProCT develop increased bone resorption with excessive osteoclast formation in both the long bones and axial skeleton. Mechanistically, ProCT inhibits the expression of key mediators involved in the recruitment of macrophages, representing osteoclast precursors. Accordingly, ProCT arrests macrophage migration and causes inhibition of early but not late osteoclastogenesis. In conclusion, our results reveal a potential role of osteoblast-derived ProCT in the bone microenvironment that is required to limit bone resorption during iPTH.

Citing Articles

The short-chain fatty acid receptors Gpr41/43 regulate bone mass by promoting adipogenic differentiation of mesenchymal stem cells.

Behler-Janbeck F, Baranowsky A, Yorgan T, Jaeckstein M, Worthmann A, Fuh M Front Endocrinol (Lausanne). 2024; 15:1392418.

PMID: 39363899 PMC: 11446854. DOI: 10.3389/fendo.2024.1392418.

A multifunctional composite scaffold responds to microenvironment and guides osteogenesis for the repair of infected bone defects.

Sun J, Zhu H, Wang H, Li J, Li B, Liu L J Nanobiotechnology. 2024; 22(1):577.

PMID: 39300539 PMC: 11411996. DOI: 10.1186/s12951-024-02823-8.

PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche.

Liu H, Liu L, Rosen C Cells. 2024; 13(5.

PMID: 38474370 PMC: 10930661. DOI: 10.3390/cells13050406.

Transcript-dependent effects of the CALCA gene on the progression of post-traumatic osteoarthritis in mice.

Jiang S, Xie W, Knapstein P, Donat A, Albertsen L, Sevecke J Commun Biol. 2024; 7(1):223.

PMID: 38396204 PMC: 10891124. DOI: 10.1038/s42003-024-05889-0.

Relationship between calcium dynamics and inflammatory status in the transition period of dairy cows.

Neves R JDS Commun. 2023; 4(3):225-229.

PMID: 37360125 PMC: 10285257. DOI: 10.3168/jdsc.2022-0348.

References

Sims N, Morris H, Moore R, Durbridge T . Increased bone resorption precedes increased bone formation in the ovariectomized rat. Calcif Tissue Int. 1996; 59(2):121-7. DOI: 10.1007/s002239900098. View

Zaidi M . Skeletal remodeling in health and disease. Nat Med. 2007; 13(7):791-801. DOI: 10.1038/nm1593. View

Parfitt A . The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 1982; 4(1):1-6. DOI: 10.1016/0221-8747(82)90002-9. View

Reginster J, Burlet N . Osteoporosis: a still increasing prevalence. Bone. 2006; 38(2 Suppl 1):S4-9. DOI: 10.1016/j.bone.2005.11.024. View

Sozen T, Ozisik L, Calik Basaran N . An overview and management of osteoporosis. Eur J Rheumatol. 2017; 4(1):46-56. PMC: 5335887. DOI: 10.5152/eurjrheum.2016.048. View

Potts Jr J, Kronenberg H, Rosenblatt M . Parathyroid hormone: chemistry, biosynthesis, and mode of action. Adv Protein Chem. 1982; 35:323-96. DOI: 10.1016/s0065-3233(08)60471-4. View

Uzawa T, Hori M, Ejiri S, Ozawa H . Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone. 1995; 16(4):477-84. DOI: 10.1016/8756-3282(95)90194-9. View

Wojda S, Donahue S . Parathyroid hormone for bone regeneration. J Orthop Res. 2018; 36(10):2586-2594. DOI: 10.1002/jor.24075. View

Calvi L, Sims N, Hunzelman J, Knight M, Giovannetti A, Saxton J . Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001; 107(3):277-86. PMC: 199196. DOI: 10.1172/JCI11296. View

10.

Powell Jr W, Barry K, Tulum I, Kobayashi T, Harris S, Bringhurst F . Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol. 2011; 209(1):21-32. PMC: 3783949. DOI: 10.1530/JOE-10-0308. View

11.

Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y . Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994; 15(6):717-23. DOI: 10.1016/8756-3282(94)90322-0. View

12.

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

13.

Jilka R, Weinstein R, Bellido T, Roberson P, Parfitt A, Manolagas S . Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104(4):439-46. PMC: 408524. DOI: 10.1172/JCI6610. View

14.

Chambers T, Moore A . The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983; 57(4):819-24. DOI: 10.1210/jcem-57-4-819. View

15.

Zaidi M, Fuller K, Bevis P, GainesDas R, Chambers T, MacIntyre I . Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study. Calcif Tissue Int. 1987; 40(3):149-54. DOI: 10.1007/BF02555699. View

16.

Zaidi M, Moonga B, Abe E . Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002; 110(12):1769-71. PMC: 151662. DOI: 10.1172/JCI17425. View

17.

Keller J, Catala-Lehnen P, Huebner A, Jeschke A, Heckt T, Lueth A . Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun. 2014; 5:5215. PMC: 4205484. DOI: 10.1038/ncomms6215. View

18.

Amara S, JONAS V, Rosenfeld M, Ong E, Evans R . Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982; 298(5871):240-4. DOI: 10.1038/298240a0. View

19.

Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel P, Reinhart K . Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. 1999; 37(8):789-97. DOI: 10.1515/CCLM.1999.119. View

20.

Hamade B, Huang D . Procalcitonin: Where Are We Now?. Crit Care Clin. 2019; 36(1):23-40. PMC: 6866676. DOI: 10.1016/j.ccc.2019.08.003. View